A History of Bone Marrow Transplantation

Hematology/Oncology Clinics of North America

Volumn 25, Issue 1, 2011, Pages 1-15

  De la Morena, M Teresa ^a   Gatti, Richard A ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone marrow transplantation; History; Primary immunodeficiency diseases

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE; CD34 ANTIBODY; DNA; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; INTERLEUKIN 9; SMALL INTERFERING RNA;

AGAMMAGLOBULINEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; BLOOD TRANSFUSION REACTION; BONE MARROW TRANSPLANTATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL (TOPIC); DEATH; DELAYED HYPERSENSITIVITY; DENSITY GRADIENT CENTRIFUGATION; DONOR SELECTION; ENCEPHALITIS; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HEPATOSPLENOMEGALY; HISTOCOMPATIBILITY; HUMAN; IMMUNOCOMPETENCE; LEUKEMIA; LEUKEMIA RELAPSE; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; NONHUMAN; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; T CELL DEPLETION; TUBERCULOSIS; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

EID: 78651096655     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.11.001     Document Type: Review

References (104)

1. Bekkum D.W., van de Vries M.J. Radiation chimaeras 1967, Logos Press, London, p. 277.
2. The Medical College of Wisconsin and The National Marrow Donor Program. Center for International Blood and Marrow Transplant Research (CIBMTR) Available at:, 2008. Accessed October 28, 2009. http://www.cibmtr.org/.
3. Good R.A., Kapoor N., Reisner Y. Bone marrow transplantation-an expanding approach to treatment of many diseases. Cell Immunol 1983, 82(1):36-54.
4. Quine W.M.E. The remedial application of bone marrow. JAMA 1896, 26:1012.
5. Tiselius A., Kabat E.A. An electrophoretic study of immune sera and purified antibody preparations. J Exp Med 1939, 69:119-131.
6. White T.F., Dougherty A. Functional alterations in lymphoid tissue induced by adrenal cortical secretion. Am J Anat 1945, 77:81-116.
7. Medawar P.B. The experimental study of skin grafts. Br Med Bull 1945, 3:79.
8. Owen R. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945, 28:400.
9. Loeb L. Heredity and internal secretion in the spontaneous development of cancer in mice. Science 1915, 42(1095):912-914.
10. Gorer P.A. The detection of antigenic differences in mouse erythrocytes by employment of immune sera. Br J Exp Pathol 1936, 17:21.
11. Snell G.D., Stevens L.C. Histocompatibility genes of mice. III. H-1 and H-4, two histocompatibility loci in the first linkage group. Immunology 1961, 4:366-379.
12. Snell G.D. Histocompatibility genes of the mouse. I. Demonstration of weak histocompatibility differences by immunization and controlled tumor dosage. J Natl Cancer Inst 1958, 20(4):787-824.
13. Snell G.D., Jackson R.B. Histocompatibility genes of the mouse. II. Production and analysis of isogenic resistant lines. J Natl Cancer Inst 1958, 21(5):843-877.
14. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172:603-606.
15. Jacobson L.O., Simmons E.L., Marks E.K., et al. Recovery from radiation injury. Science 1951, 113:510-511.
16. Barnes D.W., Ford C.E., Ilbery P.L., et al. Tissue transplantation in the radiation chimera. J Cell Physiol Suppl 1957, 50(Suppl 1):123-138.
17. Main J.M., Prehn R.T. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 1955, 15(4):1023-1029.
18. Ford C.E., Hamerton J.L., Barnes D.W., et al. Cytological identification of radiation-chimaeras. Nature 1956, 177(4506):452-454.
19. Crouch B.G., Overman R.R. Chemical protection against x-radiation death in primates: a preliminary report. Science 1957, 125(3257):1092.
20. Mathé G., Jammet H., Pendie N., et al. Transfusions et greffes de moelle osseuse homologue chez des humaine irradies a haute dose accidentellement. Nouvelle rev franc hematol 1959, 4:226.
21. Mathe G., Amiel J.L., Schwarzenberg L., et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965, 25(9):1525-1531.
22. Thomas E.D., Lochte H.L., Lu W.C., et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957, 257(11):491-496.
23. Bruton O.C. Agammaglobulinemia. Pediatrics 1952, 9(6):722-728.
24. Bruton O.C., Apt L., Gitlin D., et al. Absence of serum gamma globulins. AMA Am J Dis Child 1952, 84(5):632-636.
25. Medici M.A., Kagan R.M., Menkes J., et al. Chronic progressive panencephalitis in hypogammaglobulinemia: a literature review. Immunodeficiency. Its nature and etiological significance in human diseases 1978, 149-160. University of Tokyo Press, Tokyo. JMR Foundation (Ed.).
26. Mannick J.A., Lochte H.L., Ashley C.A., et al. Autografts of bone marrow in dogs after lethal total-body radiation. Blood 1960, 15:255-266.
27. Miller M.E. Thymic dysplasia (" Swiss agammaglobulinemia"). I. Graft versus host reaction following bone-marrow transfusion. J Pediatr 1967, 70(5):730-736.
28. Immunologic deficiency in man. Birth defects original articles series, vol. 4 1968, The National Foundation-March of Dimes, White Plains (NY). D. Bergsma, R.A. Good (Eds.).
29. de Vries M.J., Dooren L.J., Cleton F.J. Graft versus host or autoimmune lesions in the Swiss type of agammaglobulinemia. Immunologic Deficiency in Man. Birth defects original articles series, vol. 4 1968, 173. National Foundation-March of Dimes, White Plains (NY). D. Bergsma (Ed.).
30. Hong R., Cooper M.D., Allan M.J., et al. Immunological restitution in lymphopenic immunological deficiency syndrome. Lancet 1968, 1(7541):503-506.
31. Dausset J. C R Seances Soc Biol Fil 1954, 148(19-20):1607-1608. [in French].
32. van Rood J.J., van Leeuwen A., van Santen M.C. Anti HL-A2 inhibitor in normal human serum. Nature 1970, 226(5243):366-367.
33. Payne R., Rolfs M.R. Fetomaternal leukocyte incompatibility. J Clin Invest 1958, 37(12):1756-1763.
34. Amos D.B. Genetic and antigenetic aspects of human histocompatibility systems. Adv Immunol 1969, 10:251-297.
35. Amos D.B., Seigler H.F., Southworth J.G., et al. Skin graft rejection between subjects genotyped for HL-A. Transplant Proc 1969, 1(1):342-346.
36. Ceppellini R., van Rood J.J. The HL-A system. I. Genetics and molecular biology. Semin Hematol 1974, 11(3):233-251.
37. Terasaki P.I., McClelland J.D. Microdroplet assay of human serum cytotoxins. Nature 1964, 204:998-1000.
38. Simonsen M. Graft versus host reactions. Their natural history, and applicability as tools of research. Prog Allergy 1962, 6:349-467.
39. Good R.A., Martinez C., Gabrielsen A.E. Progress toward transplantation of tissues in man. Adv Pediatr 1964, 13:93-127.
40. Storb R., Epstein R.B., Bryant J., et al. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation 1968, 6(4):587-593.
41. Thomas E.D., Epstein R.B., Eschbach J.W., et al. Treatment of leukemia by extracorporeal irradiation. N Engl J Med 1965, 273:6-12.
42. Good R.A., Fisher D.W. Immunobiology: current knowledge of basic concepts in immunology and their clinical applications 1971, 305. Sinauer Associates, Stamford (CT). R.A. Good, D.W. Fisher (Eds.).
43. Good R.A. Immunologic reconstitution: the achievement and it's meaning. Birth defects original articles series, vol. 4 1968, The National Foundation-March of Dimes, White Plains (NY). D. Bergsma, R.A. Good (Eds.).
44. Gatti R.A., Meuwissen H.J., Allen H.D., et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 2(7583):1366-1369.
45. Meuwissen H.J., Gatti R.A., Terasaki P.I., et al. Treatment of lymphopenic hypogammaglobulinemia and bone-marrow aplasia by transplantation of allogeneic marrow. Crucial role of histocompatibility matching. N Engl J Med 1969, 281(13):691-697.
46. Gatti R.A., Meuwissen H.J., Terasaki P.I., et al. Recombination within the HL-A locus. Tissue Antigens 1971, 1(5):239-241.
47. Gatti R.A., Good R.A. Follow-up of correction of severe dual system immunodeficiency with bone marrow transplantation. J Pediatr 1971, 79(3):475-479.
48. Bach F.H., Albertini R.J., Joo P., et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968, 2(7583):1364-1366.
49. Meuwissen H.J., Bortin M.M., Bach F.H., et al. Long-term survival after bone marrow transplantation: a 15-year follow-up report of a patient with Wiskott-Aldrich syndrome. J Pediatr 1984, 105(3):365-369.
50. Bortin M.M. A compendium of reported human bone marrow transplants. Transplantation 1970, 9(6):571-587.
51. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975, 292(17):895-902.
52. Gatti R.A., Kemple K., Schwartzmann J., et al. HLA-D typing with lymphoblastoid cell lines. VI. Rationale and goals of data reduction. Tissue Antigens 1979, 14(3):183-193.
53. Gatti R.A., Kempner D.H., Leibold W. The role of the MHC antigens in the mature and immature host. Pediatrics 1979, 64(5 Pt 2 Suppl):803-813.
54. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983, 61(2):341-348.
55. O'Reilly R.J., Keever C.A., Small T.N., et al. The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. Immunodefic Rev 1989, 1(4):273-309.
56. Buckley R.H., Schiff S.E., Sampson H.A., et al. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol 1986, 136(7):2398-2407.
57. Dror Y., Gallagher R., Wara D.W., et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood 1993, 81(8):2021-2030.
58. Buckley R.H., Schiff S.E., Schiff R.I., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999, 340(7):508-516.
59. de Witte T., Hoogenhout J., de Pauw B., et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood 1986, 67(5):1302-1308.
60. Lowenberg B., Wagemaker G., van Bekkum D.W., et al. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1986, 1(2):133-140.
61. Rodt H., Kolb H.J., Netzel B., et al. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc 1981, 13(1 Pt 1):257-261.
62. Filipovich A.H., McGlave P., Ramsay N.K., et al. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study. J Clin Immunol 1982, 2(Suppl 3):154S-157S.
63. Filipovich A.H., McGlave P.B., Ramsay N.K., et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982, 1(8284):1266-1269.
64. Martin P.J., Hansen J.A., Thomas E.D. Preincubation of donor bone marrow cells with a combination of murine monoclonal anti-T-cell antibodies without complement does not prevent graft-versus-host disease after allogeneic marrow transplantation. J Clin Immunol 1984, 4(1):18-22.
65. Umiel T., Daley J.F., Bhan A.K., et al. Acquisition of immune competence by a subset of human cortical thymocytes expressing mature T cell antigens. J Immunol 1982, 129(3):1054-1060.
66. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98(12):3192-3204.
67. Krause D.S., Fackler M.J., Civin C.I., et al. CD34: structure, biology, and clinical utility. Blood 1996, 87(1):1-13.
68. Cashen A.F. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. Drugs Today (Barc) 2009, 45(7):497-505.
69. Greinix H.T., Worel N. New agents for mobilizing peripheral blood stem cells. Transfus Apher Sci 2009, 41(1):67-71.
70. Kessinger A., Armitage J.O., Smith D.M., et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989, 74(4):1260-1265.
71. Pidala J., Anasetti C., Kharfan-Dabaja M.A., et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15(11):1415-1421.
72. Gallardo D., de la Camara R., Nieto J.B., et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009, 94(9):1282-1288.
73. Gorin N.C., Labopin M., Blaise D., et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009, 27(24):3987-3993.
74. Gluckman E., Broxmeyer H.A., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989, 321(17):1174-1178.
75. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997, 337(6):373-381.
76. Gluckman E., Rocha V. Cord blood transplantation: state of the art. Haematologica 2009, 94(4):451-454.
77. Knutsen A.P., Wall D.A. Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience. J Clin Immunol 2000, 20(6):466-476.
78. Bhattacharya A., Slatter M.A., Chapman C.E., et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant 2005, 36(4):295-299.
79. Hacke K., Falahati R., Flebbe-Rehwaldt L., et al. Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation. Immunol Res 2009, 44(1-3):112-126.
80. Fischer A., Landais P., Friedrich W., et al. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency. Blood 1994, 83(4):1149-1154.
81. Antoine C., Muller S., Cant A., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003, 361(9357):553-560.
82. Patel N.C., Chinen J., Rosenblatt H.M., et al. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. J Allergy Clin Immunol 2008, 122(6):1185-1193.
83. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998, 91(10):3646-3653.
84. Roifman C.M., Grunebaum E., Dalal I., et al. Matched unrelated bone marrow transplant for severe combined immunodeficiency. Immunol Res 2007, 38(1-3):191-200.
85. Grunebaum E., Mazzolari E., Porta F., et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006, 295(5):508-518.
86. Railey M.D., Lokhnygina Y., Buckley R.H. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr 2009, 155(6):834-840. e1.
87. Mazzolari E., Forino C., Guerci S., et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol 2007, 120(4):892-899.
88. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005, 105(2):879-885.
89. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001, 97(6):1598-1603.
90. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008, 111(1):439-445.
91. The International Chronic Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991, 324(8):509-516.
92. Liese J., Kloos S., Jendrossek V., et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000, 137(5):687-693.
93. Jones L.B., McGrogan P., Flood T.J., et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008, 152(2):211-218.
94. Di Bartolomeo P., Di Girolamo G., Angrilli F., et al. Reconstitution of normal neutrophil function in chronic granulomatous disease by bone marrow transplantation. Bone Marrow Transplant 1989, 4(6):695-700.
95. Schettini F., De Mattia D., Manzionna M.M., et al. Bone marrow transplantation for chronic granulomatous disease associated with cytochrome B deficiency. Pediatr Hematol Oncol 1987, 4(3):277-279.
96. Seger R.A., Gungor T., Belohradsky B.H., et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002, 100(13):4344-4350.
97. Soncini E., Slatter M.A., Jones L.B., et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009, 145(1):73-83.
98. Hoffmann T., Heilmann C., Madsen H.O., et al. Matched unrelated allogeneic bone marrow transplantation for recurrent malignant lymphoma in a patient with X-linked lymphoproliferative disease (XLP). Bone Marrow Transplant 1998, 22(6):603-604.
99. Jordan M.B., Filipovich A.H. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant 2008, 42(7):433-437.
100. Qasim W., Cavazzana-Calvo M., Davies E.G., et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 2009, 123(3):836-840.
101. Isam H., Al-Wahadneh A. Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome. Saudi J Kidney Dis Transpl 2004, 15(4):489-493.
102. Duplantier J.E., Seyama K., Day N.K., et al. Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome. Clin Immunol 2001, 98(3):313-318.
103. Rao A., Kamani N., Filipovich A., et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007, 109(1):383-385.
104. Tardieu M., Lacroix C., Neven B., et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood 2005, 106(1):40-42.